Tropisetron

Tropisetron

File:Tropisetron.png
File:Tropisetron 3D.png
Clinical data
Pregnancy category	AU: X (High risk)
Routes of administration	Oral, IM
ATC code	A04AA03 (WHO)
Legal status
Legal status	AU: S4 (Prescription only) UK: POM (Prescription only)
Pharmacokinetic data
Bioavailability	~60–80%
Protein binding	71%
Metabolism	Hepatic (CYP3A4, CYP1A2, CYP2D6)
Elimination half-life	6–8 hours
Excretion	Renal, Fecal
Identifiers
IUPAC name [(1S,5S)-8-methyl-8-azabicyclo[3.2.1]oct-3-yl] 1H-indole-3-carboxylate
CAS Number	89565-68-4
PubChem CID	72165
E number	{{#property:P628}}
ECHA InfoCard	{{#property:P2566}}
Chemical and physical data
Formula	C17H20N2O2
Molar mass	284.353 g/mol
3D model (JSmol)	Interactive image
SMILES CN1C2CCC1CC(C2)OC(=O)C3=CNC4=CC=CC=C43

Tropisetron (INN) is a serotonin 5-HT₃ receptor antagonist used mainly to treat nausea and vomiting following chemotherapy, although it has been used experimentally as an analgesic in cases of fibromyalgia. The drug is available in a 5 mg oral preparation or in 2 mg intravenous form. It is marketed by Novartis in Europe, Australia and New Zealand as Navoban, but is not available in the U.S.

Adverse effects

Tropisetron is a well-tolerated drug with few side effects. Headache, constipation, and dizziness are the most commonly reported side effects associated with its use. There have been no significant drug interactions reported with this drug's use. It is broken down by the hepatic cytochrome P450 system and it has little effect on the metabolism of other drugs broken down by this system.

External links

• - Official site
• Navoban data sheet